Related Experiment Video

Updated: Dec 11, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.9K

The Efficacy and Safety of Triazavirin for COVID-19: A Trial Protocol

Xiaoke Wu1,2,3, Kaijiang Yu4, Yongchen Wang5

  • 1Department of Pharmacology & State-Province Key Laboratories of Biomedicine-Pharmaceutics of China & Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, College of Pharmacology, Harbin Medical University, Harbin 150001, China.

Engineering (Beijing, China)
|August 25, 2020
PubMed

Insights

This clinical trial evaluates Triazavirin (TZV) for treating coronavirus disease 2019 (COVID-19). Researchers are assessing TZV

Area of Science:

  • Infectious Diseases
  • Virology
  • Clinical Pharmacology

Background:

  • Coronavirus disease 2019 (COVID-19) rapidly became a global pandemic.
  • Effective antiviral treatments for COVID-19 remain limited.
  • Novel therapeutic strategies are crucial for managing the pandemic.

Purpose of the Study:

  • To investigate the efficacy and safety of Triazavirin (TZV) in treating COVID-19 patients.
  • To compare TZV with a placebo in a randomized controlled trial setting.
  • To provide evidence-based recommendations for COVID-19 treatment.

Main Methods:

  • A multicenter, blind, randomized controlled trial (RCT) involving 240 COVID-19 participants.
  • Participants received standard therapy plus either TZV or a placebo for 7 days, with a 21-day follow-up.
  • Primary outcome: time to clinical improvement; Secondary outcomes: clinical improvement rate, fever alleviation, lung inflammation absorption, viral clearance, mortality, and disease severity progression.

Main Results:

  • This section is to be populated once the trial is concluded and results are available.
  • Ongoing data collection on clinical improvement, viral load, and patient outcomes.
  • Monitoring of adverse events, liver and kidney function, and concurrent treatments.

Conclusions:

  • This ongoing RCT aims to determine the clinical utility of Triazavirin for COVID-19.
  • Results will inform clinical practice and guide treatment decisions for COVID-19.
  • The study will contribute valuable data on TZV's safety and effectiveness against SARS-CoV-2.

Keywords:
Coronavirus disease 2019EfficacyPneumoniaSARS-CoV-2SafetyTriazavirin

More Related Videos

High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication10:16

High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication

Published on: October 30, 2021

4.0K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.2K

Related Concept Videos

Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
71
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.0K
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
820
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
102
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
116